Low-dose XXXX in the treatment of neurologic disorders: experience in @entity3148 .

@entity4899 @entity1 @entity410 @entity353 @entity21938 @entity74 @entity302 @entity3148
UNASSIGNED: In this paper, we review the experience with @entity4899 in @entity302 and other @entity74 . Since the best available data are from the treatment of @entity3148 , we will focus primarily on this condition. Originally @entity4899 was launched as an anorectic agent. As early as 1985, @entity410 reduction in @entity1 could be demonstrated in a few cases with photosensitive, self-induced @entity302 . Hereafter, a small study was launched in @entity1 with self-induced @entity302 . Results showed a significant @entity410 reduction, and review of the @entity1 data showed that 5 of the 12 @entity1 had @entity3148 . During that observation period, @entity4899 was withdrawn from the market because of cardiovascular side effects associated with prescribing higher doses in combination with @entity21938 for @entity353 . In March 2002, a Belgian Royal Decree was issued permitting further study of @entity4899 in pediatric @entity1 with intractable @entity302 . In 2011 under the Royal Decree, a prospective study of @entity1 with @entity3148 treated with low-dose @entity4899 was initiated and is currently ongoing. The initial results are promising in terms of reduction of @entity410 frequency and overall tolerability.
